No significant gastrointestinal disorder that, in the opinion of the Investigator, could interfere with the absorption of entinostat and/or sorafenib tosylate including any of the following: [clinicaltrials_resource:0fe0c51a084e56599abea7af5a898157]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
No significant gastrointestinal disorder that, in the opinion of the Investigator, could interfere with the absorption of entinostat and/or sorafenib tosylate including any of the following: [clinicaltrials_resource:0fe0c51a084e56599abea7af5a898157]
Bio2RDF identifier
0fe0c51a084e56599abea7af5a898157
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0fe0c51a084e56599abea7af5a898157
identifier
clinicaltrials_resource:0fe0c51a084e56599abea7af5a898157
title
No significant gastrointestina ...... any of the following:
@en
type
label
No significant gastrointestina ...... 0c51a084e56599abea7af5a898157]
@en